677304-83-5 Usage
Description
7-Benzothiazolecarboxylic acid (9CI) is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical agents. It is characterized by its benzothiazole ring structure and carboxylic acid functional group, which contribute to its reactivity and potential applications in medicinal chemistry.
Uses
Used in Pharmaceutical Industry:
7-Benzothiazolecarboxylic acid (9CI) is used as a chemical intermediate for the synthesis of pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). These inhibitors play a crucial role in regulating gene expression and have potential therapeutic applications in treating various diseases.
Additionally, 7-Benzothiazolecarboxylic acid (9CI) is utilized in the preparation of aminofuro-pyridine derivatives, which act as inhibitors of TAK1 (Transforming Growth Factor-β Activated Kinase 1). TAK1 inhibition can modulate inflammatory and immune responses, making these derivatives valuable in the development of treatments for inflammatory and autoimmune disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 677304-83-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,7,3,0 and 4 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 677304-83:
(8*6)+(7*7)+(6*7)+(5*3)+(4*0)+(3*4)+(2*8)+(1*3)=185
185 % 10 = 5
So 677304-83-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H5NO2S/c10-8(11)5-2-1-3-6-7(5)12-4-9-6/h1-4H,(H,10,11)
677304-83-5Relevant articles and documents
2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES
-
, (2009/10/18)
The invention relates to novel 2-aza-bicyclo[2.2.1]heptane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as m
INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF
-
Page/Page column 71, (2010/02/14)
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
